Mounjaro carries a list price of roughly $1,023 to $1,094 per month without insurance, depending on the dose. That number is what you’d face at the pharmacy counter if no discount or coverage kicks in. But the actual amount you pay can range from as little as $25 a month to the full sticker price, depending on your insurance, your diagnosis, and whether you qualify for savings programs.
List Price vs. What You Actually Pay
Eli Lilly, the maker of Mounjaro, lists the drug at just over $1,000 for a one-month supply. At the lowest starting dose (2.5 mg), the cash price runs about $1,094 for two prefilled pens. Higher doses used later in treatment cost roughly the same per fill because each box still contains the same number of pens.
Very few people pay full list price, though. If you have commercial insurance that covers Mounjaro, Eli Lilly offers a savings card that can bring your copay down to as little as $25 for up to a three-month supply. If your plan only allows one-month fills, the savings card still applies at $25 per fill. The catch: you need active commercial (private) insurance, and the drug has to be on your plan’s formulary or at least partially covered.
If your insurance doesn’t cover Mounjaro at all, or you’re uninsured, that savings card won’t help, and you’re looking at roughly $1,000 a month out of pocket. Some patients turn to independent prescription discount programs, but the savings there are modest compared to the full retail price.
Why Your Diagnosis Changes the Price
Mounjaro is FDA-approved for type 2 diabetes, not weight loss. The same active ingredient, tirzepatide, is sold under a different brand name, Zepbound, specifically for weight management. This distinction matters because insurance companies decide coverage based on the approved use.
If your doctor prescribes Mounjaro for type 2 diabetes, insurance is far more likely to cover it, especially after you’ve tried other diabetes medications first. Most plans require prior authorization, meaning your doctor submits paperwork showing you meet certain criteria: a type 2 diabetes diagnosis, inadequate blood sugar control on other medications, and no disqualifying conditions like type 1 diabetes or a history of certain thyroid cancers.
If you’re seeking tirzepatide purely for weight loss and don’t have type 2 diabetes, your doctor would typically prescribe Zepbound instead. Without insurance, Zepbound’s price ranges from about $300 to $1,069 per month depending on the dose and where you fill it. Some pharmacies and discount programs price the lower doses significantly cheaper than Mounjaro’s equivalent. With insurance coverage for obesity, your cost could be lower still, but weight loss medications face stricter coverage limits than diabetes drugs at most insurers.
Medicare and Government Coverage
Medicare has historically not covered medications prescribed solely for weight loss. That’s changing, but slowly. Starting July 1, 2026, a new program called the Medicare GLP-1 Bridge will give eligible Part D beneficiaries access to certain weight loss drugs, including Zepbound, through the end of 2027. Mounjaro itself isn’t on the Bridge program list since it’s the diabetes brand, but the weight loss versions of tirzepatide (Zepbound KwikPen) are included.
To qualify for the Bridge program, you’ll need a BMI of 35 or higher, or a BMI of 30 or higher with certain conditions like uncontrolled high blood pressure, heart failure, or stage 3a kidney disease. At a BMI of 27 or above, you may still qualify if you have pre-diabetes, a history of heart attack or stroke, or peripheral artery disease. Your prescriber will need to submit prior authorization confirming you meet these thresholds and that you’re combining the medication with diet and exercise changes.
Medicaid coverage varies by state and is generally limited. If you have VA benefits, tirzepatide is available but typically restricted to patients with type 2 diabetes who haven’t achieved blood sugar goals on other treatments.
No Generic Option Yet
There is no FDA-approved generic version of tirzepatide. The compound is a complex injectable peptide, which makes it harder to replicate than a simple pill, and Eli Lilly holds patents that protect exclusivity for years to come.
Some compounding pharmacies previously made custom versions of tirzepatide at lower prices while the drug was in shortage. The FDA has since clarified that tirzepatide is no longer on the national drug shortage list, which limits compounders’ ability to legally produce it. Compounded versions are not reviewed by the FDA for safety or effectiveness, and their availability is shrinking.
Realistic Monthly Costs by Situation
- Commercial insurance covers it (with savings card): As low as $25 per month
- Commercial insurance with high copay (with savings card): $25 per month in most cases, since the card covers the difference
- Insurance doesn’t cover it: $1,000 to $1,100 per month at retail
- No insurance: $1,000 to $1,100 per month, though pharmacy discount tools may trim this slightly
- Medicare (current): Not covered for weight loss; covered for diabetes under Part D with formulary restrictions
- Medicare (starting July 2026): Zepbound (same ingredient) covered through the Bridge program for qualifying patients
What Drives Long-Term Cost
Mounjaro and Zepbound are not one-time treatments. Clinical data shows that most people regain weight after stopping tirzepatide, which means you may need to stay on the medication indefinitely to maintain results. At $1,000 a month without coverage, that adds up to over $12,000 a year.
Dose escalation also affects cost timing. You start at the lowest dose and increase every four weeks based on how your body responds. While the per-box price stays roughly the same regardless of dose, some insurance plans tier their copays differently for higher doses, and prior authorization may need renewal as you move up.
If you’re considering Mounjaro or Zepbound for weight loss, the most important first step is checking whether your specific insurance plan covers either drug, and for which diagnosis. Your pharmacy can run a test claim, or your insurer’s formulary lookup tool can tell you where the drug sits on their coverage tiers before you commit to a prescription.